Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years

Daniel J. Lovell, Nicolino Ruperto, Richard Mouy, Eliana Paz, Nadina Rubio-Pérez, Clovis A. Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A. Melo-Gomes, Claudia Saad-Magalhaes, J. Chavez-Corrales, Christian Huemer, Alan Kivitz, Francisco J. Blanco, Ivan Foeldvari, Michael Hofer, Hans Iko Huppertz, Chantal Job Deslandre, Kirsten MindenMarilynn Punaro, Alan J. Block, Edward H. Giannini, Alberto Martini, Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years'. Together they form a unique fingerprint.

Medicine & Life Sciences